M
Mark Downes
Researcher at Canterbury Hospital
Publications - 5
Citations - 2391
Mark Downes is an academic researcher from Canterbury Hospital. The author has contributed to research in topics: Renal artery & Stent. The author has an hindex of 5, co-authored 5 publications receiving 2283 citations.
Papers
More filters
Journal ArticleDOI
Renal sympathetic denervation in patients with treatment-resistant hypertension (The Symplicity HTN-2 Trial): A randomised controlled trial
Murray D. Esler,Henry Krum,Paul A. Sobotka,Markus P. Schlaich,Roland E. Schmieder,Michael Böhm,Felix Mahfoud,Horst Sievert,Nina Wunderlich,Lars Christian Rump,Oliver Vonend,Michael Uder,Mel Lobo,Mark J. Caulfield,Andrejs Erglis,Michel Azizi,Marc Sapoval,S. Thambar,Alexandre Persu,Jean Renkin,Heribert Schunkert,Joachim Weil,Uta C. Hoppe,Tony Walton,Dierk Scheinert,Thomas Binder,Andrzej Januszewicz,Adam Witkowski,Luis M. Ruilope,Robert Whitbourn,Heike Bruck,Mark Downes,Thomas F. Lüscher,Alan G. Jardine,Mark Webster,Thomas Zeller,Jerzy Sadowski,Krzysztof Bartus,Craig A. Straley,Neil C. Barman,David P. Lee,Ronald M. Witteles,Vivek Bhalla,Joseph M. Massaro +43 more
TL;DR: Catheter-based renal denervation can safely be used to substantially reduce blood pressure in treatment-resistant hypertensive patients and should be continued, according to the authors.
Journal ArticleDOI
Sirolimus-Eluting versus Bare-Metal Low-Profile Stent for Renal Artery Treatment (GREAT Trial): Angiographic Follow-up after 6 Months and Clinical Outcome up to 2 Years:
Markus Zähringer,Marc Sapoval,Peter M. T. Pattynama,Claudio Rabbia,Claudio Vignali,Geert Maleux,Louis Boyer,Malgorzata Szczerbo-Trojanowska,Werner Jaschke,Geir Hafsahl,Mark Downes,Jean-Paul Beregi,Nic J. G. M. Veeger,Hans-Peter Stoll,Aly Talen +14 more
TL;DR: The angiographic outcome at 6 months did not show a significant difference between BMS and SES, and future studies with a larger patient population and longer angiography follow-up are warranted to determine if there is a significant benefit of drug-eluting stents in treating ostial renal artery stenosis.
Journal ArticleDOI
Low-profile stent system for treatment of atherosclerotic renal artery stenosis : The GREAT trial
Marc Sapoval,Markus Zähringer,Peter M. T. Pattynama,Claudio Rabbia,Claudio Vignali,Geert Maleux,Louis Boyer,Malgorzata Szczerbo-Trojanowska,Werner Jaschke,Geir Hafsahl,Mark Downes,Jean Paul Beregi,Nic J. G. M. Veeger,Aly Talen +13 more
TL;DR: The Palmaz Genesis stent (Cordis) provides good results for renal artery stent placement, with an in-stent binary restenosis rate (percent diameter stenosis > 50%) at 6 months of 14.3% as determined with angiography.
Journal ArticleDOI
Injection-associated pain in femoral arteriography: A European multicenter study comparing safety, tolerability, and efficacy of iodixanol and iopromide
TL;DR: Iodixanol 270 mg I/ml causes significantly less injection-associated pain during femoral arteriography and is as safe and efficatious as iopromide 300 mg I-ml.
Journal ArticleDOI
One Year Clinical Outcomes of Renal Artery Stenting: The Results of ODORI Registry
Marc Sapoval,I. Tamari,Pierre Goffette,Mark Downes,Q. Senechal,Fabrizio Fanelli,P. Reimer,Z. Negaiwi,P. De Cassin,Sam Heye,V. Korobov,D. Tsetis,H. Abada +12 more
TL;DR: In hypertensive patients with atherosclerotic renal artery stenosis Tsunami peripheral balloon-expandable stent provides a safe revascularization strategy, with a potential beneficial impact on hypertension control and renal function in the highest risk patients.